BRCA1 and neoplasm: A phase 1 trial has evaluated the combination of olaparib with cediranib in pretreated TNBC patients with or without BRCA1/2 mutation; however, the trial observed limited anti-tumor activity (no objective response and 2 SD in 8 patients), likely due to the small sample size.